Elevating the Future of Cancer care with Alpha Theranostics

Accelerate.EU, a collaborative European initiative, envisions revolutionising theranostics through innovative targeted alpha-therapies (TATs) using astatine-211.

A unique consortium will combine diagnostics with potent cytotoxic effects of alpha-particles to enable precise tumour radiation while minimising side effects.

Accelerate.EU's core objectives are:Innovate theranostic solutions based on therapeutic and diagnostic pairs for hard-to-treat cancers, exploring the potential for simultaneous preclinical studies and early-phase clinical trials (i.e. co-clinical approach) to showcase the enhanced benefits of these approaches for cancer patients.Establish a robust and sustainable EU manufacturing and treatment infrastructure for astatine-211, ensuring compliance with quality assurance and regulatory guidelines while streamlining the supply chain across the EU.Produce comprehensive educational and training content to support the deployment of theranostic solutions, fostering knowledge dissemination, transfer and longevity/durabilityAccelerate.EU strategically develop TATs to address unmet clinical needs in pancreatic, breast, and brain cancers.

The co-clinical approach, incorporating concurrent clinical and preclinical studies, adds a breakthrough dimension to theranostics.

Accelerate.EU pioneers 211At-theranostics establishing a resilient EU scale-up production network and empowering healthcare providers to offer TATs to cancer patients.

Through the collaboration of experts from academia, industry and regulatory agencies, Accelerate.EU's implements a visionary approach addressing clinical gaps, accelerating TAT theranostic development, supporting EU global leadership, with primary target to improve patient outcomes for lasting impact on EU cancer care.